The authors of the original article, Clin Sci (Lond) (2023) 137 (9): 727-753, would like to correct their paper. The monoclonal antibody depemokimab described as anti-IL-5R, have been corrected to anti-IL5 in the following statement and in the revised Table 2 provided below.
Table 2. Targeting immune mechanisms in T2 and non-T2 inflammation.
| Target | Approach | Name | Company | Patients | Status/clinical phase |
|---|---|---|---|---|---|
| IgE | |||||
| IgE (Cε3 domain-site involved in binding to FcRI) | humanized IgG1 MoAb | omalizumab | Novartis | Asthma urticaria CRSwNP |
approved |
| IgE (Cε3 domain) | humanized MoAb | ligelizumab | Novartis | asthma urticaria |
3 |
| IgE (M1 segment) | humanized MoAb | quilizumab | Genentech | asthma | 2 |
| IgE (Cε3 domain) | humanized MoAb | MEDI4212 | MedImmune LLC | Asthma | 1 |
| CεmX domain of membrane-bound IgE | humanized MoAb | FB825 | Oneness Biotech Co | Asthma | 2 |
| IL-4/IL-13 | |||||
| IL4Ra (subunit common to IL-4 and IL-13 receptors | human MoAb | dupilumab | Regeneron/Sanofi | atopic dermatitis asthma CRSwNP EoE |
approved |
| IL-4+IL-13 receptors | recombinant IL-4 variant | pitrakinra | Aerovance | atopic dermatitis asthma |
2 |
| IL-4+IL-13 | 2 MoAbs (VAK694+dectrecumab) | QBX258 | Novartis | asthma | 2 |
| IL-4R | suman IgG2 MoAb | AMG317 | Amgen | asthma | 2 |
| IL-4 | humanized MoAb | pascolizumab | GSK | asthma | 3 |
| IL-4 | human MoAb | VAK694 | Novartis | asthma, pollinosis | 2 |
| IL-4 | soluble recombinant IL-4R | altrakincept | Amgen | asthma | terminated |
| IL-13 | humanized MoAb | lebrikizumab | Lilly | atopic dermatitis | 3 |
| IL-13 | human MoAb | tralokinumab | LeoPharma | atopic dermatitis | approved |
| IL-13 | humanized MoAb | anrukinzumab | Wyeth | asthma | 2 |
| IL-13 | humanized MoAb | GSK679586 | GSK | asthma | 2 |
| IL-13 | human MoAb | dectrecumab (QAX576) | Novartis | eosinophilic esophagitis | 2 |
| IL-13 receptor α1 subunit (IL-13Rα1) | human MoAb | ASLAN 004 | Aslan Pharmaceuticals | eczema | 1 |
| IL-5 | |||||
| IL-5 | humanized IgG1 MoAb | mepolizumab | GSK | asthma, EGPA HES CRSwNP |
approved |
| IL-5 | humanized MoAb | reslizumab | Teva | asthma | approved |
| IL-5Ralpha | humanized MoAb | benralizumab | AstraZeneca | asthma | approved |
| IL-5 | long acting MoAb | depemokimab | GSK | asthma | 3 |
| Other molecules regulating T2 inflammation | |||||
| TSLP | humanized MoAb | tezepelumab | AstraZeneca/Amgen | asthma | approved |
| TSLP | neutralizing antibody fragment (inhaled form) | CSJ117 | Novartis | asthma | 2b |
| TSLP receptor | human MoAb | ASP7266 | Upstream Bio | asthma | 1 |
| IL-33 | MoAb | tozorakimab/MEDI3506 | AstraZeneca | asthma | 2 |
| IL-33 | human MoAb | itepekimab | Regeneron/Sanofi | asthma | 2 |
| ST2 (IL-33R) | MoAb | astegolimab | Hoffmann-La Roche | asthma | 2b |
| IL-33R | MoAb | melrilimab (GSK3772847) | GSK | healthy subjects | 1 |
| IL-25 | MoAb | ABM125 | Abeome | asthma | 1/2 |
| Tryptase tetramers | MoAb | MTPS9579A | Roche/Genetech | astma | 2a |
| CRTh2(PGD2 receptor) | antagonist (small molecule) | fevipiprant QAW039) | Novartis | asthma | terminated |
| CRTh2(PGD2 receptor) | antagonist (small molecule) | setipiprant | Actelion | asthma | 2 |
| IL-9 | humanized MoAb | enokizumab | AstraZeneca/MedImmune | asthma | 2 |
| IL-22 | human MoAb | fezakinumab | Rockefeller University | atopic dermatitis | 2 |
| IL-31 | humanized MoAb | nemolizumab | Galderma | atopic dermatitis | 3 |
| CCR3 (eotaxin receptor) | inhibitor (small molecule) | GW766944 | Glaxo | asthma | 2 |
| Singlec 8 | humanized MoAb | lirentelimab | Allakos Inc. | atopic dermatitis eosinophilic esophagitis and duodenitis | 2, 3 |
| Potential targets in non T2 inflammation | |||||
| IL-17 | humanized MoAb | secukinumab | Novartis | asthma | terminated, * |
| IL-17RA | human MoAb | brodalumab | Amgen | asthma | terminated |
| C5 | humanized MoAb | eculizumab | Alexion | asthma | 2 |
| CXCR2 | receptor antagonist (small molecule) | AZD5069 | AstraZeneca | asthma | 2 |
| CXCR1/2 | receptor antagonist (small molecule) | SCH527123 | MSD | asthma | 2 |
| IL-6 | humanized MoAb | tocilizumab | Roche | asthma | small proof‐of‐concept clinical trial, * |
| IL-1 | rIL-1 receptor antagonist | anakinra | Sobi | asthma | 2, * |
| IL-1 alpha | human MoAb | bermekimab | Janssen | atopic dermatitis | 2b |
| Reactive aldehyde species (RASP) | RASP inhibitor (small molecule) | ADX-629 | Aldeyra | asthma | 2 |
| TNF | TNFR:Fc | etanercept | Sobi | asthma | 2, * |
| TNF | chimeric MoAb | infliximab | MSD | asthma | 2, * |
| TNF | human MoAb | golimumab | Centocor | asthma | 2, * |
*) other indications have been previously approved (within rheumatology; inflammatory bowel disease, psoriasis, autoinflammatory diseases, etc)
Furthermore, benralizumab showed efficacy in patients with severe CRSwNP by decreasing nasal blockage score in a randomized placebo controlled study [229] Depemokimab, a long-acting anti-IL-5 monoclonal antibody, is currently being evaluated in phase III clinical trials in severe uncontrolled asthma with an eosinophilic phenotype (NCT04719832).